液体使用量的决定因素及液体量与平衡溶液对重症患者死亡率影响的关联:BaSICS 试验的二次分析
该研究为 BaSICS 试验的二次分析,比较 0.9% 氯化钠与 Plasma-Lyte 148®(平衡溶液)在 ICU 液体治疗中的效果,共分析 10,505 例患者。平衡溶液组与 0.9% 氯化钠组液体用量中位数分别为 2500 mL 与 2488 mL。贝叶斯回归中随机效应(入组中心)解释了全部模型方差的 0.32(95% 可信区间 0.24-0.41),频率学派混合模型与随机森林结果相似。仅纳入第 3 天仍存活且留在 ICU 的患者时,液体用量与平衡溶液效应之间呈现强烈交互提示,主要由脓毒症患者液体用量增加时平衡溶液较 0.9% 氯化钠死亡率更低所驱动;贝叶斯网络分析和基于中心实践的分析结果一致,高液体用量中心入组平衡溶液的脓毒症患者死亡率更低(绝对风险降低 -0.13,95% 可信区间 -0.27 至 -0.01;获益概率 0.98)。
要点
- 在 BaSICS 试验 10,505 例患者中,前 3 天液体用量更多由入组中心(随机效应)而非基线患者特征解释,随机效应占模型方差 0.32(95% CrI 0.24-0.41)。
- 平衡溶液组与 0.9% 氯化钠组前 3 天液体用量中位数分别为 2500 mL 与 2488 mL。
- 第 3 天仍存活且留在 ICU 的患者中,液体用量与平衡溶液效应存在强烈交互提示,主要由脓毒症患者液体用量增加时平衡溶液较 0.9% 氯化钠死亡率更低所驱动。
- 高液体用量中心入组平衡溶液的脓毒症患者死亡率更低,绝对风险降低 -0.13(95% CrI -0.27 至 -0.01),获益概率 0.98。
适用人群与场景
- BaSICS 试验纳入的 ICU 患者,共分析 10,505 例;亚组分析聚焦第 3 天仍存活且留在 ICU 的患者以及脓毒症患者。
研究设计与关键结果
- 研究类型:BaSICS 试验的二次分析,比较 0.9% 氯化钠与 Plasma-Lyte 148®(平衡溶液)用于 ICU 液体治疗。
- 样本量:10,505 例患者;平衡溶液组与 0.9% 氯化钠组前 3 天液体用量中位数分别为 2500 mL 与 2488 mL。
- 贝叶斯回归中随机效应(入组中心)解释全部模型方差 0.32(95% CrI 0.24-0.41);频率学派模型与随机森林结果相似。
- 仅纳入第 3 天仍存活且留在 ICU 的患者时,液体用量与平衡溶液效应之间呈现强烈交互提示,主要由脓毒症患者液体用量增加时平衡溶液较 0.9% 氯化钠死亡率更低所驱动。
- 基于中心实践的分析中,高液体用量中心入组平衡溶液的脓毒症患者死亡率更低:绝对风险降低 -0.13(95% CrI -0.27 至 -0.01),获益概率 0.98。
证据类型、等级与局限
- 证据类型:随机对照试验(BaSICS)的二次分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,BaSICS 试验中收集的基线患者特征对前 3 天液体用量方差的解释少于入组中心。
- 作者认为,液体用量与平衡溶液效应似乎存在交互,主要在脓毒症亚组中,入组后液体用量与平衡溶液对 90 天死亡率的影响存在强关联。
指南或共识出处
- BaSICS 试验(Balanced Solution in Intensive Care Study)的二次分析,发表于 Intensive Care Medicine。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Fluid use could modulate the effect of balanced solutions (BS) on outcome of intensive care unit (ICU) patients. It is uncertain whether fluid use practices are driven more by patient features or local practices. It is also unclear whether a "dose-response" for the potential benefits of balanced solutions exists.
METHODS: The secondary analysis of the Balanced Solution in Intensive Care Study (BaSICS) compared 0.9% saline versus Plasma-Lyte 148® (BS) for fluid therapy in the ICU. The relative contribution of patient features and enrolling site (the random effect) on the volume of fluid used up to day 3 after admission was assessed using different methods, including a Bayesian regression, a frequentist mixed model, and a random forest, all adjusted for relevant patient confounders. Subsequently, a variety of methods were used to assess whether volume of fluid used modulated the effect of BS on 90-day mortality, including a traditional subgroup analysis for patients that remained alive and in the ICU up to 3 days, a Bayesian network accounting for competing risks, and an analysis based on site practices.
RESULTS: 10,505 patients were analyzed. Median fluid use in the BS arm and in the 0.9% saline arm were 2500 mL and 2488 mL, respectively. The random effect in the Bayesian regression explained 0.32 (95% credible intervals (CrI) 0.24-0.41) of all model variance (0.33, 95% credible intervals from 0.32-0.35). Frequentist and random forest models produced similar results. In the analysis including only patients alive and in the ICU at 3 days, there was a strong suggestion of interaction between fluid use and the effect of BS, driven mostly by a lower mortality with BS compared to 0.9% saline as fluid use increased for patients with sepsis. These results were consistent in the Bayesian network analysis and in an analysis based on site practices, where septic patients enrolled to BS at high fluid use sites had a lower mortality (absolute risk reduction of - 0.13 [95% credible interval - 0.27 to - 0.01]; 0.98 probability of benefit).
CONCLUSION: Baseline patient characteristics collected in the BaSICS trial explain less of the variance of fluid use during the first 3 days than the enrolling site. Volume of fluid used and the effects of BS appear to interact, mostly in the sepsis subgroup where there was a strong association between fluid use after enrollment and the effect of BS on 90-day mortality.
参考来源
- Zampieri FG, Machado FR, Veiga VC, et al. Determinants of fluid use and the association between volume of fluid used and effect of balanced solutions on mortality in critically ill patients: a secondary analysis of the BaSICS trial. Intensive Care Med. 2023. PMID: 38010383. doi:10.1007/s00134-023-07264-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。